Extended-Release Calcifediol Identifies a Therapeutic Vitamin D Range in Chronic Kidney Disease stage 3-4

Clicks: 1
ID: 317029
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #101 of 127 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 127 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD) driven by dysregulated vitamin D metabolism. The serum 25-hydroxyvitamin D (25D) levels required for targeted intact parathyroid hormone (iPTH) reductions are poorly defined, and conventional sufficiency thresholds of 20 or 30 ng/mL are inadequate. Exposure–response (E–R) modeling was used to define a 25D range associated with a 30% iPTH reduction during treatment with extended-release calcifediol (ERC). Methods E–R relationships between 25D and iPTH were evaluated using pooled data from randomized clinical trials of ERC in participants with SHPT, CKD stage 3–4, and vitamin D insufficiency. Mixed-effects models characterized % change in iPTH as a function of concurrent 25D. Mechanistic analyses evaluated associations between 25D, its key metabolites, and iPTH. Associations between achieved 25D and markers of mineral metabolism were assessed. Results E–R modeling demonstrated a nonlinear relationship between 25D and iPTH reduction with a population-average of 84 ng/mL associated with 30% iPTH reduction (ER30), ranging from 67–103 ng/mL across the range of kidney function. Baseline body weight and sex significantly influenced achieved 25D concentrations. Higher achieved 25D was not associated with adverse changes in calcium, phosphorus, or fibroblast growth factor-23. Circulating 1,25-dihydroxyvitamin D was not independently associated with iPTH response. Conclusions Elevation of 25D to 84 ng/mL (range: 66.9–102.6 ng/mL) during ERC treatment was associated with a 30% iPTH reduction in participants with SHPT, CKD stage 3–4, and VDI. This range was unassociated with adverse changes in mineral metabolism.
Reference Key
openalex_W7164331329 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors John Choe, Akhtar Ashfaq, Charles W. Bishop
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag194
URL
https://doi.org/10.1093/ckj/sfag194
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.